Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.

Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review

Bandeira, Igor D., Lins-Silva, Daniel H., Cavenaghi, Vitor Breseghello, Dorea-Bandeira, Ingrid, Faria-Guimarães, Daniela, Barouh, Judah L., Jesus-Nunes, Ana Paula, Beanes, Graziele, Souza, Lucca S., Leal, Gustavo C., Sanacora, Gerard, Miguel, Euripedes C., Sampaio, Aline S., Quarantini, Lucas C. · 2022 · Harvard Review of Psychiatry

Abstract

Introduction: First-line treatment for obsessive-compulsive disorder (OCD) includes exposure and response prevention behavioral therapy and serotonin reuptake inhibitors, particularly in combination. New and more effective treatments are needed, give that recent studies suggest that glutamatergic neurotransmission contributes to the pathophysiology of the disorder. In these circumstances, ketamine, as a potent N-methyl-D-aspartate receptor antagonist and glutamate modulator, offers alternative possibilities for OCD treatment. Methods: This systematic review aims to investigate the effects of ketamine in OCD, following the Preferred Reporting Items for Systematic Review and Meta-analyses Protocols (PRISMA-P). Searches were carried out using the PubMed/MEDLINE, Embase, and PsycINFO databases. Results: Nine articles were included, of which three were randomized controlled trials, three case reports, two open-label trials, and one a retrospective chart review. Reported data have shown a potential for fast onset of action and good tolerability of ketamine for OCD, even though the principal studies used only single-session racemic ketamine treatments, administered intravenously, and the results have been erratic. In addition, none of the available evidence demonstrates whether racemic ketamine, S-ketamine, or R-ketamine has the best efficacy in controlling OCD symptoms, and only sparse evidence suggests that a combination of ketamine and psychotherapy could benefit patients with OCD. Conclusion: In order to advance clinical practice regarding the use of ketamine in treating OCD, future randomized, double-blind, placebo-controlled trials are required. These trials need to use larger samples to explore ketamine and its enantiomers, with different methods of administration, multiple sessions, and appropriate washout periods.

Overview

Integrity signals

Registry

Crossref · 10.1097/hrp.0000000000000330

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 82 references

Cited by

See all 39

Metadata

Authors
Bandeira, I. D., Lins-Silva, D. H., Cavenaghi, V. B., Dorea-Bandeira, I., Faria-Guimarães, D., Barouh, J. L., Jesus-Nunes, A. P., Beanes, G., Souza, L. S., Leal, G. C., Sanacora, G., Miguel, E. C., Sampaio, A. S., & Quarantini, L. C.
Affiliations
Universidade Federal da Bahia (BR)
Corresponding author
  • Bandeira, Igor D.
  • Lins-Silva, Daniel H.
Venue
Harvard Review of Psychiatry
Published
2022-03
Volume
30
Issue
2
Pages
135-145
ISSN
  • 1067-3229 (ISSN-L)
  • 1465-7309
OpenAlex
W4220741313
Cited by
39
References
82
Citations by year
2026: 10 · 2025: 6 · 2024: 9 · 2023: 11 · 2022: 3
FWCI
1.21
Type
journal article
Language
en
Open access
closed
Locations
  • Harvard Review of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
ketamine, obsessive-compulsive disorder, NMDA receptor antagonists, glutamatergic neurotransmission, esketamine, (R)-ketamine, ketamine enantiomers, rapid onset of action, tolerability, intravenous administration
MeSH terms
Humans, Ketamine, Obsessive-Compulsive Disorder, Retrospective Studies, Treatment Outcome, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review. https://app.cochat.ai/papers/10.1097/hrp.0000000000000330
The paper
Bandeira, I. D., Lins-Silva, D. H., Cavenaghi, V. B., Dorea-Bandeira, I., Faria-Guimarães, D., Barouh, J. L., Jesus-Nunes, A. P., Beanes, G., Souza, L. S., Leal, G. C., Sanacora, G., Miguel, E. C., Sampaio, A. S., & Quarantini, L. C. (2022). Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review. Harvard Review of Psychiatry. https://doi.org/10.1097/hrp.0000000000000330

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.